ESPR vs RARE

For growth investors, Esperion Therapeutics, Inc.

(ESPR) is the stronger pick with 21. 3% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Ultragenyx Pharmaceutical Inc.

(RARE) delivered a total return of -77. 2%, compared to -85. 9% for Esperion Therapeutics, Inc. (ESPR). Over 10 years, the gap is even starker: RARE returned -59. 4% versus ESPR's -79. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ultragenyx Pharmaceutical Inc.

(RARE) is the lower-risk stock at 1. 42β versus Esperion Therapeutics, Inc. 's 2. 33β — meaning ESPR is approximately 64% more volatile than RARE relative to the S&P 500.

By revenue growth (latest reported year), Esperion Therapeutics, Inc.

(ESPR) is pulling ahead at 21. 3% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Esperion Therapeutics, Inc. grew EPS 60. 7% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, ESPR leads at 74. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Esperion Therapeutics, Inc.

(ESPR) is the more profitable company, earning -5. 6% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps -5. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ESPR leads at 15. 0% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Esperion Therapeutics, Inc. (ESPR) carries a higher beta of 2. 33 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (RARE: -59. 4%, ESPR: -79. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.